In an interview with ACT senior editor Andy Studna at the 2025 DIA Global Annual Meeting, Carie Pierce, SVP, global head of ...

Brian Ongioni, chief product officer, uMotif, shares how early collaboration with patients and clinical sites helps shape intuitive, accessible digital health tools—and why co-design is key to ...

As wearable ECG technology advances, cardiac safety studies in clinical trials are evolving to capture richer, continuous ...

Peter Ronco, CEO, Emmes, explains why AI in clinical development still needs human oversight despite widespread hype.

In an interview with ACT senior editor Andy Studna at the 2025 DIA Global Annual Meeting, Carie Pierce, SVP, global head of ...

In our June issue, explore how clinical research is adapting to regulatory changes, AI advancements, and modernizing trial ...

Peter Ronco, CEO, Emmes, explains how public sector leaders are driving innovation in clinical development through automation, long-term data utilization, and experimental trial design—despite the ...

Using a recent survey on the adoption of AI/ML conducted by the Tufts CSDD as context, pharma leaders discussed how they are using these technologies to optimize trial execution.

Balancing the emerging benefits of AI in pharmacovigilance with new responsibilities and demands from regulators in enhancing ...

In this Q&A, Megan Bailey, EVP and president of central laboratories and international, Labcorp, discusses how central labs ...

Navigating a complex drug development landscape, sponsors must rethink their approach to risk in study design and execution.

In this video interview, Matt Robinson, PhD, senior director, oncology research program, National Comprehensive Cancer ...